Palermo

Running trials

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Source

• Recruiting

  REAL-CARE: Real-world Effectiveness of Iptacopan in Italian Patients With Paroxysmal Nocturnal Hemoglobinuria

  NCT07229235· Source

• Recruiting

  Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population

  NCT07543419· Source

• Active, not recruiting

  Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

  NCT07093801· Source

• Recruiting

  A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

  NCT06649110· Phase 1/2· Source

• Active, not recruiting

  ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

  NCT06345157· Source

• Active, not recruiting

  Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

  NCT05548062· Source

• Active, not recruiting

  CINC424A2X01B Rollover Protocol

  NCT02386800· Phase 4· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Hidradenitis suppurativa1 recruiting
• High blood pressure1 recruiting
• Pulmonary arterial hypertension1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

  NCT05376579· Source

• Completed

  Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD

  NCT04023552· Phase 3· Source

• Terminated

  Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant

  NCT03439046· Phase 3· Source